All posts by imreal

Ibaoviet Is Here to Help with the Perfect Insurance Package


News Image

In today’s society, more and more companies are losing faith in physical stores and they choose to do business either entirely or partially online. For many industries, this approach is working really well. Purchasing insurance online is getting more and more popular, even in Vietnam.

Ibaoviet keeps up with today’s changes in the society and they are offering their customers the possibility to purchase online insurance packages. Customers who need insurance are no longer required to go to a physical store to buy the insurance they need. Online insurance has the convenience of being available at all hours of the day. Gone are the days when the only time customers could have purchased insurance was between 9 and 5.

At Ibaoviet, all the information the customers need is posted transparently on their website. However, customers who have some difficulties in understanding some terms or need consulting before making a purchase can easily contact them. Their team of dedicated professionals is always ready and they can be contacted directly via phone or through Viber, Zalo, Hotline, and email.

Purchasing insurance from Ibaoviet, can help customers save money. Purchasing insurance online skips, the middleman, which is the insurance agent. By not having to pay an insurance agent, Ibaoviet can save money that can be used to offer more advantageous insurance packages. Furthermore, they offer deals and discounts all year round.

Life Insurance

Ibaoviet’s life insurance solution was created to help people protect themselves against risks related to their health, body, and life. This type of insurance can pay for different expenses such as medical examination, treatment costs, surgical expenses, and hospitalization expenses. Ibaoviet was selected by Global Banking and Finance Review as the best provider of life insurance in Vietnam. Having more than 15 million protected customers, Ibaoviet is always ready to help potential customers build a flexible solution to protect themselves and their loved ones. Potential customers can choose a life insurance package depending on the needs and age of the persons they want to insure.

Health Insurance

Private health insurance is a type of non-life insurance that is completely voluntary and is provided by insurance companies Ibaoviet is offering health insurance packages that can protect both children and adults. Ibaoviet is there when things are not ok, and they are committed to offering quick and fair compensation. The interests of the customers are always the first priority. Their health insurance packages can satisfy the needs of different categories of potential customers such as uninsured persons, persons who want to be treated abroad, persons who want to access high-quality health care, or pregnant women who want to use high-quality maternal services.

Accident Insurance

While working, studying, or enjoying life, people are always at risk of having an accident. Ibaoviet’s accident insurance packages provide cover to the insured and its dependents against the financial strain that can occur in case of an accident. The coverage of the accident insurance package includes the following: accidental death benefit, partial disability benefit, permanent disability benefit, cover of medical expenses arising from the treatment of the injury, allowances during hospitalization.

Car Insurance

Car insurance is an expensive service that anyone needs in order to legally drive a vehicle in Vietnam. Ibaoviet is offering three types of car insurance: compulsory car insurance, car material insurance, and car insurance for the people inside the vehicle. Compulsory car insurance will pay for the damages done by an insured vehicle to another vehicle or propriety. Car material insurance will reimburse the owner of the policy if the vehicle is damaged in events that can’t be controlled such as crashing, overturning, fire, hurricanes, earthquakes, storms, flood, theft, and others. The accident insurance package for people sitting inside the vehicles like drivers, or passengers, will reimburse the costs to treat the injuries suffered in an accident.

Travel Insurance

Travel insurance can help customers deal with various risks, illnesses, or accidents that can occur when traveling to a foreign land. Ibaoviet is offering international and domestic travel insurance packages. There are several reasons why travelers should purchase this type of insurance. This insurance will cover the cost of lost luggage, flight cancellation, stolen wallet or passport, damages that are done to propriety, injuries done to a person, or if the insured needs immediate medical assistance.

Technical Propriety Insurance

The technical propriety insurance is an insurance package that can help cover the damages done to mechanical and technical proprieties. Property damage to work equipment and machines, or during building projects can occur suddenly and without warning. This risk can seriously affect companies and cause downtime. Technical propriety insurance can reimburse the policyholders in the following cases: collisions with vehicles or animals that are not under the control of the insured, damage done by earthquakes, volcanoes, thunderstorms, floods, fire, or explosion of residential boilers, theft, and robbery.

In addition to the insurance packages described above, Ibaoviet has many other packages created to cover all types of damages and situations. Just contact them and check their insurance packages. Ibaoviet offers the best insurance packages for the best insurance premiums.

For more info about the company’s services, visit their website: https://ibaoviet.vn/.

MEDIA CONTACT

Address: Phong ban hang bao hiem Bao Viet So 19, Duong 21, Phuong 10, Quan 6, HCM.

Map: https://goo.gl/maps/v76KtUtHSUgjQGZq7

Email: kinhdoanh@ibaoviet.vn

SOCIAL LINKS

Facebook – https://www.facebook.com/ibaoviet/

Twitter – https://twitter.com/ibaoviet

Behance – https://www.behance.net/ibaoviet

Tello – https://trello.com/ibaoviet/activity

Share article on social media or email:



Trella Health Named a Preferred Vendor by National Partnership for Hospice Innovation


Trella Health, the leading source for current and complete post-acute outcomes data and provider performance analytics, recently became a Preferred Vendor of the National Partnership for Hospice Innovation (NPHI), an organization driven by passion and integrity to help people live fully through the end of life. The partnership will expand opportunities to positively impact the hospice community through strategic initiatives.

“Everyone should have the right to pass in dignity and comfort in their home, surrounded by their loved ones,” states Ian Juliano, CEO of Trella Health. “We are humbled by the opportunity to become a preferred vendor and partner for NPHI, the work their members do is so incredibly important, and we want to do all we can to help them be successful.”

As a preferred vendor, Trella Health will be involved in sponsoring NPHI activities, such as the Annual Summit, relevant Innovation Lab projects, and various forums throughout the year. Additional collaboration will include webinars and case studies with industry education for NPHI members. NPHI members will also benefit from special pricing on Trella’s solution and services. In addition, Trella Health will provide a portion of the revenue generated from NPHI members to NPHI to help fund NPHI’s mission and innovative initiatives.

“NPHI members are committed to improving upon current best practices in advanced illness, hospice, and palliative care delivery and applying hospice principles throughout the care continuum,” said Tom Koutsoumpas, NPHI President & CEO. “NPHI is distinguished through our innovative partnerships and we are excited to be able to offer every member discounted access to Trella’s strong platform.”

Recent examples of Trella’s commitment to the hospice community include a COVID-19 heatmap, which visualizes counties with large populations of high-risk Medicare patients, and an upcoming study quantifying hospice’s end of life impact on both cost and patient outcomes. As a preferred vendor, Trella looks forward to strong, mutually beneficial partnership grounded in NPHI’s goals and mission.

About Trella Health

Trella Health provides post-acute business development leaders with the most complete picture of care activity in their service areas, allowing them to increase their patient census and bottom line by identifying new opportunities for growth. As one of only a few companies in the country deemed ‘Innovators’ under the Center for Medicare and Medicaid Service’s Virtual Research Data Center Program, Trella has access to 100% of Medicare Part A and Part B claims data. Trella analyzes 1.2 billion claims annually and presents relevant insights to nearly 10,000 users so they can build higher-performing care networks, serve more patients, and reduce the cost of care. For more information on Trella Health, visit https://www.trellahealth.com/.

About NPHI

The National Partnership for Hospice Innovation (NPHI) is a collaborative of 70+ not-for-profit, community-integrated, advanced illness, hospice, and palliative care providers across the United States who play a unique role as a crucial safety net for the sickest, most vulnerable patients in the communities they serve. For more information or to find advanced illness and hospice care in your area, visit http://www.hospiceinnovations.org.

Share article on social media or email:

Dr. Mark Leondires, Founder and Medical Director of RMA of Connecticut, to Participate in NASDAQ/Progyny Sponsored Webinar on LGBTQ Family-Building and Benefit Trends


Dr. Mark Leondires of RMA of Connecticut and Gay Parents To Be will join NASDAQ and Progyny for an LGBTQ Family-Building webinar

Dr. Mark Leondires to join NASDAQ and Progyny for an LGBTQ Family-Building webinar

“Speaking up for the rights of LGBTQ people who want to be parents and have equal access to family-building benefits, will hopefully and eventually lead to a world with family-building coverage for everyone,” says Dr. Mark Leondires

RMA of Connecticut, a leading fertility practice whose exceptional quality and care helps couples and individuals grow their family, has announced its founder and medical director, Dr. Mark Leondires, a leader and advocate for LGBTQ+ family-building equality and the founder of Gay Parents To Be, an international program serving the LGBTQ+ community offered through RMA of Connecticut, will participate in the NASDAQ/Progyny sponsored webinar, Understanding LGBTQ+ Family Building + Benefit Trends.

The webinar, Understanding LGBTQ+ Family Building + Benefit Trends, is a featured Pride Month event, and will be held on Wednesday, June 17th from 1:00pm – 2:00pmEST. The panel will be moderated by NASDAQ’s Head of Client Engagement, Josh Machiz and will feature two other distinguished panelists including Bonnie Sechrist, Director of Health Management Consulting at Willis Tower Watson and Lisa Greenbaum, Chief Client Officer at Progyny. The webinar will be open to the public in addition to NASDAQ’s client network and can be accessed through Zoom. Topics for discussion will include LGBTQ family-building options (including surrogacy, adoption, and reciprocal IVF), equitable fertility and family-building benefits trends, and what it means for employers that are behind the curve in offering inclusive benefits.

“It’s an honor to speak at the NASDAQ/Progyny-sponsored webinar, Understanding LGBTQ+ Family Building + Benefit Trends,” said Dr. Mark Leondires, founder of RMA of Connecticut, Gay Parents To Be, and Gays with Kids. “While many companies are making major strides in offering inclusive fertility benefit coverage for all people, there is still work to be done. Speaking up for the rights of LGBTQ people who want to be parents and have equal access to family-building benefits, will hopefully and eventually lead to a world with family-building coverage for everyone.”

“Now more than ever, family comes first,” said Lisa Greenbaum, Chief Client Officer at Progyny, a leading fertility benefits management company in the US. “It is imperative that employers and physicians, like Dr. Leondires, work together to advocate for the LGBTQ+ community and ensure that all employees have equitable family building benefits.”

In the race to attract and retain top talent, companies have begun offering inclusive benefits, a step in the right direction when it comes to equal benefits and fertility coverage for LGBTQ persons. Dr. Mark Leondires will speak about LGBTQ pathways to parenthood and the importance for more companies to offer equitable family-building benefits to all employees.

Gay Parents To Be was created and conceived by Dr. Mark Leondires. He has very personal knowledge of the LGBTQ family-building experience and is uniquely qualified as a gay father of two and a top reproductive endocrinologist to help couples through the process. Dr. Leondires spends his spare time advocating for large corporations to provide equitable family-building benefits for all employees.

For additional information and to sign up for the webinar, please visit, https://nasdaq.zoom.us/webinar/register/WN_Xr8jXS8ORaek5nSKZaXB_A

About Reproductive Medicine Associates of Connecticut (RMA of Connecticut)

RMA of Connecticut is a leader in fertility care, specializing in a range of infertility treatments. Our assisted reproductive technologies (ART) include intrauterine insemination (IUI), in-vitro fertilization (IVF) and pre-implantation genetic testing (PGT). RMA of Connecticut is Fairfield County’s largest fertility clinic and egg donation center. Through RMA of Connecticut’s Integrated Fertility and Wellness Center, we offer nutrition counseling, individual and couples psychological counseling, acupuncture and yoga, as well as financing and support services for our patients going through infertility treatment.

Our internationally recognized Gay Parents To Be® program at RMA of Connecticut specializes in LGBTQ family building. For the last three years, RMA of Connecticut has been recognized as a Leader in Healthcare Equality by the Human Rights Campaign.

Share article on social media or email:

Blue Spark Technologies’ TempTraq® Wearable Temperature Monitor Compatible with U.S. Military’s BATDOK™ Software Application


TempTraq a disposable, wireless patch that continuously monitors patient temperature

“We are pleased that we have been able to make our technology compatible with this essential military tool that supports our armed forces medical needs,” said John Gannon, Blue Spark president and chief executive officer.”

Blue Spark Technologies, Inc. today announced that its TempTraq® wearable temperature monitor — a disposable, wireless patch that continuously monitors patient temperature — has been deemed compatible with the Battlefield Assisted Trauma Distributed Observation Kit (BATDOK™) remote patient monitoring software. This point-of-injury monitoring and documentation tool allows physicians or specialists to consult remotely with the U.S. military on the battlefield while also transmitting patient data and vitals in real-time to medical personnel.

The goal of BATDOK is to increase the simplicity and accuracy of documenting injury and health status in high-stress, fast-paced environments, ultimately allowing providers to treat more patients. Blue Spark worked with the United States Air Force Research Lab (AFRL) to develop a TempTraq compatible plug-in that enables BATDOK users to continuously monitor the temperature of patients for up to 72 hours and have the data transmitted wirelessly via Bluetooth® to a dashboard in real time.

“We are pleased that we have been able to make our technology compatible with this essential military tool that supports our armed forces medical needs,” said John Gannon, Blue Spark president and chief executive officer. “Providing constant temperature monitoring will not only provide critical healthcare information, but also be used to monitor military personnel as part of any program developed for monitoring military personnel for COVID-19.”

Beyond compatibility with BATDOK and support of U.S. military personnel, TempTraq® is being used in the fight against the COVID-19 pandemic. University Hospitals, one of the largest hospital systems in Ohio, is using TempTraq® for continuous monitoring of its caregivers during the COVID-19 pandemic to ensure that any caregivers who spike a high temperature can quickly be identified and evaluated. The technology is also being used in Australia at Royal Prince Alfred Hospital to monitor COVID-19 positive patients recovering at home as part of a virtual hospital program that was created to help mitigate a potential hospital overflow caused by the pandemic.

Implemented in hospitals across the United States, Europe and Australia, TempTraq® is supported by both patient- and clinician-facing mobile apps with data centrally stored on TempTraq connect, a HIPAA-compliant cloud service. Data monitoring is also available on the TempTraq® Clinician web portal or routed directly to hospital EMRs.

For more information about TempTraq®, visit https://temptraq.healthcare.

About TempTraq®

TempTraq®, Blue Spark Technologies’ patented innovation, is the only Bluetooth®, wearable temperature monitor in the form of a soft, comfortable patch that continuously, safely and comfortably monitors body temperature for up to 72 hours and sends alerts to Apple® or Android™ compatible mobile devices.

TempTraq Connect is the HIPAA-compliant cloud service supported by Google Healthcare Cloud Platform that enables patients and caregivers to monitor body temperature from anywhere. It can also directly integrate with healthcare provider electronic medical record (EMR) systems and nurse monitoring stations, providing a secure method of storing patient healthcare data. The system is FDA, CE and TGA cleared.

TempTraq has shown proven efficacy in the most demanding environments, including the Cleveland Clinic, University Hospitals Seidman Cancer Center and Cincinnati Children’s Hospital, as well as several other leading hospitals. The TempTraq system is scalable and can support a single hospital or a multi-hospital/physician group healthcare system. Headquartered in Westlake, Ohio, Blue Spark Technologies, Inc. is an innovator in wearable, medical device solutions.

Share article on social media or email:

Infrawear Obtains FDA IV.D Status Alongside Exclusive Deal with Genesprint for Worldwide Distribution of PCR Swab and NCOV-19 IGM/ IGG Antibody Test Kits for COVID-19


News Image

Infrawear LLC, the go-to resource for medical professionals, hospitals, first responders, and companies with critical PPE and COVID-19 testing and antibody kits, today announced that it has obtained its IV.D status from the FDA. As an FDA IV.D (4D) listed and registered Class 2 medical device importer, the company is leveraging its deep operational supply chain experience to source and import critical PPE and COVID-19-specific tests as the exclusive distributor and partner for Genesprint Group Ltd., a leading research and manufacturing company for on-site antibody diagnostic kits for various infectious disease. As their exclusive worldwide distribution partner, Infrawear is able to sell their high-demand, PCR Swab and NCOV-19 IGM/ IGG Antibody Test Kits for COVID-19. Additionally, the FDA just listed Genesprint’s serology antibody test on their emergency notification list, enabling Infrawear to to distribute to anyone who has a CLIA lab or is certified to work with a CLIA lab. Additionally, they’ve increased capacity and can get tests to most doctor’s offices with NEXT DAY delivery.

“We’re amazed at what our agile team has been able to accomplish to help hospitals and medical professionals in the U.S. in just a short amount of time,” said Rachael McCrary, co-founder and President of Infrawear. “Our team has such deep supply chain experience and operational expertise that, after seeing the immediate need, we were quickly able to tap into our existing relationships and create an effective, affordable and, most critically, a reliable solution to aid in the fight against COVID-19. We’re thankful for our partnership with Genesprint, who knew how nimble we could be and didn’t go with a large corporation for distribution, due to our reputation for being able to get things done quickly and effectively.”

Infrawear has an established history of having the deepest level of sourcing and shipping expertise and supply chain know-how. Since the COVID pandemic, the Company has already built new relationships with more than 100+ hospitals, government agencies, and corporations across the U.S., in less than four months’ time. Infrawear is rapidly providing top-quality, high-demand medical supplies, tests and PPE to clinical laboratories or to healthcare workers for point-of-care testing covered by a laboratory’s CLIA certification for high-complexity testing, with ease and efficiency.

In partnership with Genesprint, Infrawear is one of the few companies that to outpace demand by easily sourcing and distributing these much needed, life-altering tests rapid tests for COVID-19. There are two types of tests offered: the PCR Swab Test (patent-pending) for COVID-19 virus testing, and the NCOV-19 IGM/ IGG antibody test kit and Nucleic Acid Collector that tests for COVID antibodies past and present. Testing is key in getting America back to work and back to normalcy, and Genesprint tests are known for their high-accuracy, accessibility and affordability. Where other large testing companies have reportedly only received 50,000 tests per month, Genesprint can produce 20 million per month. Their tests are available in the U.S. through Infrawear now, with shipments coming in daily for medical professionals to deliver antibody test results within 15 minutes and COVID-19 test results within three hours’ time.

“We’re making mass screening more accessible to those in need,” said Jonathan Sweetser, CTO at Infrawear. “The beauty of working with Infrawear is that physicians, medical professionals, and any company with medical staff don’t have to have to go through the bureaucracy or red tape to simply get needed supplies in-hand, without the hassle. By providing ease of access to the high-demand supplies, putting them in hands of those in need for today’s ever and rapidly-evolving medical demands, Infrawear is helping those in need at a much faster rate than large testing companies.”

Infrawear has experienced growth by more than 100% MoM. The Company’s ability to quickly provide effective and accurate tests at U.S. laboratories and hospitals is expected to improve and help flatten the infection curve.

About Infrawear, LLC

Infrawear, LLC is the go-to resource for medical professionals, hospitals and first responders for critical PPE and COVID-19 testing and antibody kits. We have a passion for innovation and an established track record for getting things done quickly and efficiently. As an FDA IV.D (4D) notify listed and registered Class 2 medical device importer, the company leverages its deep operational supply chain experience to source and import critical PPE and supplies such as N95 masks, gowns, testing kits and antibody tests. As the exclusive distributor and partner for Genesprint Group Ltd. we provide access to their sought after rapid COVID-19 tests, including NCOV-19 IGM/ IGG antibody test kit as well as its PCR Swab Test for COVID-19. Infrawear is also the parent company of RxBra, which manufactures proprietary vertical, and post-surgical garments to plastic surgeons. Our company is recommended by the American Hospital Association and is well-known for providing ease of access to high-demand supplies, putting them in the hands of those in need for today’s ever and rapidly-evolving medical demands. Infrawear LLC is a US-based company headquartered in Los Angeles, with offices in New York and Ohio. Learn more by visiting: Infrawear.com

About Genesprint Group Ltd

Genesprint Group Ltd is a Hong Kong based testing company founded by Dr. Paul Tam, with their lab and research team being led by Dr. Sherman Fung, Dr. Chi C. Wong. They have been developing research and manufacturing for on-site antibody diagnostic kits for various infectious diseases for more than three years. Recently, they launched the rapid tests for COVID-19, which can deliver results within minutes and provide mass screening to the general population.

About the PCR Swab Test for COVID-19

The Genesprint PCR Swab is patent-pending in Hong Kong and is only available in the U.S. through Infrawear, LLC. The test is made of nylon and is optimized for specimen collection. GP swab relates to the field of swabs, in particular to a swab optimized for specimen collection. In one embodiment, the swab comprises a stem having two ends at opposite sides along its longitudinal axis, and having a tip portion defined as an area proximate and terminating at an end of said stem; a layer of fiber strands attached to and covering said tip portion, said fiber strands are attached to said tip portion at a substantially perpendicular angle against said tip portion; wherein said layer of fiber strands forms a hydrophilic open fiber morphology and facilitates absorption of a fluid through capillary effect; said layer of fiber strands further optimizes elution of a specimen contained in said fluid. In a preferred embodiment, the nylon fiber strands are electrostatically charged. This swab has a better performance with liquid intake and release compared to existing swabs, such as cotton wound swabs.

About the Antibody Test for COVID-19 – NCOV-19 IGM/ IGG antibody test kit and Nucleic Acid Collector

Our sensitivity can detect as early as 2.5 days of exposure. The Serology Antibody finger prick test when compared to a PCR test:

  • Accuracy: 98.75
  • Sensitivity: 98.75
  • Specificity: 98.74
  • We have 85% accuracy on early onset


PRESS CONTACT:

Nicole Rodrigues

NRPR Group

(650) 815–5069

Nicole@nrprgroup.com

Share article on social media or email:

Catalent Partners with Spicona to Develop COVID-19 Vaccine Candidate using GPEx® Cell Line Development Platform


We feel privileged to start this collaboration with Catalent, which we consider the best partner for the development of a novel COVID-19 vaccine candidate. Together, our two experienced teams will work toward finding a safe and efficacious solution to prevent COVID-19 as soon as possible.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19. Under the terms of the agreement, Catalent will use its proprietary GPEx® cell line development technology to develop a cell line expressing the recombinant VLP at its Madison, Wisconsin facility.

Spicona is focused on research and development in the field of immunology and vaccinology. Its pipeline is being built around novel compounds for the prevention and treatment of infectious diseases, with an immediate focus on the development of a novel, safe and protective COVID-19 vaccine. Spicona is led by a team of experienced vaccine experts headed by Dr. Kaspar Bänziger, Dr. Reinhard Glück, and Dr. Gaurav Gupta, together with a prestigious international advisory board, whose members have been involved in the development of several vaccines, including the severe acute respiratory syndrome (SARS) vaccine in 2003. Today, millions of children and adults are safely immunized with vaccines developed and brought to market by the experts who make up the Spicona team.

Catalent’s GPEx technology creates stable, high-yielding mammalian cell lines with high speed and efficiency. The advantages of applying GPEx technology span from early feasibility studies to clinical manufacturing, through to commercial-scale production. GPEx technology is used with therapeutic candidates in more than 120 ongoing clinical trials.

“We feel privileged to start this collaboration with Catalent, which we consider the best partner for the development of a novel COVID-19 vaccine candidate,” commented Kaspar Bänziger, CEO, President, Spicona, Inc. “Together, our two experienced teams will work toward finding a safe and efficacious solution to prevent COVID-19 as soon as possible.”

“Catalent’s GPEx technology and the Madison facility provide proven technology and expertise that are a perfect fit for Spicona’s unique vaccine approach to address COVID-19.” commented Mike Riley, Region President, Catalent Biologics, North America. He added, “We are pleased to be working with Spicona and other partners on all major classes of COVID-19 vaccines in development.”

Catalent’s Madison facility provides mammalian cell line development, process development, process validation, formulation development and drug substance manufacturing ranging from pre-clinical to commercial stage. The site recently commenced an expansion to provide additional clinical and commercial production capacity at the 2,000 or 4,000-liter batch scale.

About Spicona

Spicona is focused on research and development in the field of immunology and vaccinology and is currently building a pipeline of novel compounds for the prevention and treatment of infectious diseases. The company is led by a team of experienced vaccine experts headed by Dr. Kaspar Bänziger, Dr. Reinhard Glück and Dr. Gaurav Gupta, who have developed several new vaccines, including a SARS vaccine in 2003, and brought multiple successfully to the market. Today, millions of children and adults are immunized with these vaccines. Spicona’s immediate focus is the research and development of a novel, safe and protective COVID-19 vaccine. Spicona is headquartered in New York City, NY. For more information, visit http://www.spicona.com

About Catalent Biologics

Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx® cell line development technology, and manufactured 35+ commercially approved products. Catalent has recently acquired MaSTherCell, a technology-focused cell therapy development and manufacturing partner with expertise in autologous and allogeneic cell therapy that complements Catalent’s industry-leading expertise and commercial success in gene therapy development, manufacturing and adeno-associated virus (AAV) vector production. Together, Paragon Gene Therapy and MaSTherCell have produced over 100 GMP batches across 60+ clinical and commercial programs. For more information on Catalent Biologics, visit http://www.catalent.com/biologics

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

Majority of Americans fear for their health due to delaying routine care as a result of corona-19


“Telemedicine has been an invaluable alternative for seeing a healthcare provider during the pandemic,” says Grace Earl, Clinical Associate Professor of Pharmacy Practice at Fairleigh Dickinson University, School of Pharmacy & Health Sciences.

Many Americans believe their overall health will suffer as they avoid medical treatment out of fears of getting COVID-19, and few are confident that a coronavirus vaccine, should it become available, will be adequately tested and safe for use. Additionally, more than one-in-four adults nationwide think hydroxychloroquine, the malaria drug touted by President Trump, is a safe and effective treatment for the coronavirus, despite multiple studies showing otherwise. These are some of the findings from a new national survey conducted on behalf of the Fairleigh Dickinson University School of Pharmacy and Health Sciences from Fairleigh Dickinson University by the FDU Poll.

According to the survey, a majority of those polled (54%) are very to somewhat concerned that their own or a loved one’s health is at risk due to delaying treatment for non-COVID-19-related medical problems because they fear doing so would put them at risk of catching the virus. In fact, more than a quarter (27%) say they will not go to a doctor’s office except for emergencies until a vaccine or treatment for COVID-19 is available.

While resistance to seeking out medical treatment will likely have a long-lasting impact on Americans’ health, telehealth as an alternative to in-person medical care has gained traction during the pandemic and is enabling patients to be seen virtually by health practitioners.

Telehealth Gets Good Marks

The survey found that 24 percent of those polled have seen a doctor or other health professional via online video conferencing since the pandemic began in March, with 72 percent saying their experience was the same or better than an in-person medical visit. Although the number of Americans who actually have used these technologies is still fairly limited, three-quarters (76%) of Americans say they would be comfortable having a telehealth appointment with their doctor if they were unable to see them face-to-face.

“Telemedicine has been an invaluable alternative for seeing a healthcare provider during the pandemic. It allows people to continue to seek medical treatment while protecting themselves from COVID-19 by limiting their exposure to other people,” explained Grace Earl, Clinical Associate Professor of Pharmacy Practice at Fairleigh Dickinson University, School of Pharmacy & Health Sciences. “However, this research does show that there are barriers to the use of these technologies, with more than a quarter of those who had a telehealth experience saying it was worse than an in-person appointment. While some people may never be happy with virtual care, making these technologies as easy-to-use and glitch-free as possible would help improve the experience for others.”

Among those who said they would not go online for an appointment (24%), a majority said they would avoid this option out of concerns they would get the treatment they need (56%). Another 32 percent cite difficulty in navigating the technology needed, and eleven percent say privacy concerns make telehealth not an option.

Americans were also asked about the degree of concern they may have for their own or a loved one’s health due to delays in medical treatment that might occur because of the pandemic. A full half (54%) of Americans say they are very or somewhat concerned that their own health, or that of a loved one, will suffer because of not getting or delaying medical treatment for a non-COVID-19 related health condition out of fear of contracting the disease. A full 26 percent say they are very concerned.

Vaccines Lack Confidence

Key to getting society back to normal is a vaccine for the virus. And, while there has been a huge push to get this accomplished quickly – the Trump administration even naming the effort “Operation Warp Speed” – Americans have mixed views of whether it will be done safely. When asked how much confidence they have that any vaccine that becomes available will have been adequately tested for effectiveness and deemed safe for use, most Americans are not totally convinced that this will happen. Only one-in-five (20%) say they are very confident, with 28% who say they are not at all confident, and around half (52%) who are somewhat confident.

As for whether Americans would get a vaccine if and when it becomes available, 29% say they definitely will. Another third (36%) probably will, with 35% saying they are unlikely or definitely will not get a coronavirus vaccine. Democrats (37%) more than Republicans (25%) are among the “definitely will,” while Republicans (26%) more than Democrats (5%) are among the “definitely will not.”

“The hesitation that Americans have, and their distrustful view of vaccine development may serve as an obstacle to vaccine acceptance in the future. A significant amount of education on the benefits and risks of the vaccine will need to be provided to the public,” explained Julie Kalabalik-Hoganson, Chair and Associate Professor of Pharmacy Practice, Fairleigh Dickinson University School of Pharmacy and Health Sciences.

Black Americans are particularly skeptical when it comes to their faith in vaccines. More than a third of blacks have no confidence in the deployment of a safe and effective vaccine, as compared to about a quarter of white Americans (26%) and Hispanic Americans (27%). They are also the most likely to say they will exercise restraint when it comes to getting the coronavirus vaccine, assuming it becomes available. Forty-three percent of blacks say they probably or definitely will not get the vaccine. This is significantly more than the number of whites (25%) and Hispanic Americans (35%) who express similar uncertainty.

“The gap that separates blacks from whites also extends to their concerns about their overall health. It’s important to note that black respondents are significantly more concerned than whites about their own or a loved one’s health due to disruptions in medical care. Almost half of all blacks surveyed say they’re very concerned, with less than half that number among whites. Almost a third of white Americans are not at all concerned that the pandemic will cause their health to suffer as compared with only 15 percent of Black Americans,” said Krista Jenkins, professor of politics and government and director of the poll.

In addition to the importance of a coronavirus vaccine is the yearly flu vaccine. Americans have been urged by medical leaders to get their flu vaccine to protect them from next year’s strain. Doing so will lessen the pressure on the healthcare system should another wave of coronavirus peak in the fall and beyond. The message seems to have been heard by many Americans, as almost two-thirds (62%) indicate they are likely to get the vaccine for the coming flu season. If true, this would be a significant increase over those who regularly get the flu vaccine (54%).

“With fears of a second wave of coronavirus in the fall, it is predicted there will be a peak in COVID-19 cases in December 2020. Managing the second wave on top of the flu season will be challenging and may place a substantial strain on the healthcare system. Flu vaccination and COVID-19 testing will play an important role in reducing hospitalizations and minimizing spread of illness,” explained Kalabalik-Hoganson.

(Mis)information

While there is a great deal of COVID-19 misinformation circulating, a majority of Americans are able to distinguish between what’s true and false. However, there remain large numbers of Americans who believe information that is untrue about the virus. Almost one-in-three (31%) believe taking Motrin or Advil will make COVID-19 worse, 28% say Hydroxychloroquine is safe and effective for treating the virus, and 18% believe blood pressure medications should be avoided if you have COVID-19.

And finally, Americans are uncertain when it comes to the numbers of infections and deaths attributed to the coronavirus. Only 16% believe coronavirus infections have been reported accurately, with slightly more (21%) who say the same about the number of coronavirus related deaths. Most believe the numbers either over- or under-state the infection and death rate in the United States. More people believe the number of infections and deaths are under-reported (57% and 41%, respectively), as compared to those who believe they are over-reported (27% and 38%).

The Trump Effect

Attitudes toward President Trump help to distinguish respondents across some of the questions related to what people know about the virus. For example, among those who approve of the job the president has done in managing the nation’s response to the virus, half believe incorrectly that hydroxychloroquine is a safe and effective way to treat COVID-19, as compared with 80% who correctly identify this as a false statement among those who disapprove of his leadership. And, in regard to attitudes toward the reasons behind contradictory information about the virus from the president, half of those who believe he allows science to guide his advice say incorrectly that hydroxychloroquine is safe. Among those who believe he bows to political pressure when dispensing advice, 78% correctly identify this as a false statement.

And how one evaluates the reported incidence of infections and death from the virus is also related to views of the President. Half of those who approve of his leadership believe the infections have been overreported, and 66% of the same group believe the number of deaths are overstated. Conversely, around three-fourths of those who disapprove of his leadership believe infections have been underreported (77%) and 62 percent of the same group believe coronavirus related deaths are underreported.

“You can’t hear hydroxychloroquine without thinking of the president, so perhaps it’s no surprise that among his supporters we find a greater chance that someone believes in the drug’s safety and efficacy” said Krista Jenkins, professor of politics and government and director of the poll. “He’s a powerful source of information to his supporters, even when there is clear evidence that refutes his messages.”

Methodology

The survey was conducted by The Fairleigh Dickinson University Poll on behalf of the FDU School of Pharmacy and Health Sciences. A random sample of 1003 was drawn of adults (18+) nationwide, including in Alaska and Hawaii, and live interviews were conducted in English and Spanish, upon request, on landlines and cell phones between May 20 through May 25, 2020. Persons without a telephone could not be included in the random selection process. Respondents within a household are selected by asking randomly for the youngest adult currently available. The interview was conducted in English and included 303 adults reached on a landline phone and 700 adults reached on a cell phone, all acquired through random digit dialing.

In this poll, the simple sampling error for 1003 adults is +/-3.6 percentage points (including the design effect) at a 95 percent confidence interval. Thus, if 50 percent of adults nationwide in this sample favor a particular position, we would be 95 percent sure that the true figure is between 46.4 and 53.6 percent (50 +/- 3.6) if all US adults had been interviewed, rather than just a sample.

The full analysis, along with the poll’s questions and tables and a detailed methodological statement, can be found on the FDU Poll website.

About Fairleigh Dickinson University

Devoted to the preparation of world citizens, Fairleigh Dickinson University offers over 100 undergraduate and graduate degree programs, including doctoral programs in pharmacy, nursing practice, clinical psychology and school psychology; and an AACSB-accredited business school. Degree programs are offered on two New Jersey campuses and at two international campuses: Wroxton College, in Oxfordshire in England, and the Vancouver Campus, in British Columbia, Canada. For more information, visit FDU.edu.

About FDU Poll

The FDU Poll is a university based survey research center that began in 2001. It has conducted over a hundred publicly released polls guided by a mission to provide high quality, scientifically sound, non-partisan measures of important issues facing New Jersey and the nation. To learn more visit us online

About FDU’s School of Pharmacy & Health Sciences

The Fairleigh Dickinson University School of Pharmacy & Health Sciences is one of only two degree-granting pharmacy schools in New Jersey, and is the first in the state to be associated with a private university. The School’s dynamic program of study integrates the very best practices in pharmacy education today. The school has also expanded its presence in the field of public health and health professions with the addition of health sciences programs such as Master of Public Health, Master of Social Work, Occupational Therapy and Physician Assistant.

West Point Cadets and Annapolis Midshipmen Lead the Way in Serving Aging Veterans During the COVID Pandemic and Address Racial Justice Issues Through Their Example


Operation Golden Shield

Protecting Our Veterans and Supporting Our Caregivers

Operation Golden Shield was established by a coalition of West Point cadets and Annapolis midshipmen to serve aging Veterans during this unprecedented time of the COVID-19 pandemic. With almost 2 million cases and over 110,000 deaths in the United States alone, the coronavirus remains a significant threat to many vulnerable populations to include Veterans in nursing homes. This student-led community effort aims to collect and donate priority items for Veterans in long-term care facilities and urgently needed medical supplies for the care providers caring for them.

Operation Golden Shield also serves as a positive counter point to the heightened racial tensions and rhetoric of recent days and provides a shining example of what color-blind collaboration and solidarity look like. Despite national protests against the killings of George Floyd and others, the calls for racial justice and remedies for the fault lines of systemic inequities, and the shifting landscape of political dialogue, Operation Golden Shield’s organizing committee is an incredibly diverse leadership group consisting of cadets and midshipmen of all races and ethnicities. They are serving Veterans and their caregivers and doing so in Washington, DC, where 75% of COVID-19 deaths are among African-Americans. Their leadership and service are exemplars of what our nation should aspire to.

Operation Golden Shield was founded by Caleb Suh – a first year cadet at the United States Military Academy and a graduate of James Madison High School in Vienna, Virginia – who coordinated with the Community Living Center (CLC) at the D.C. VA Medical Center to identify the most urgent needs of health care providers and of CLC residents. The next drive-by donation event is scheduled for Saturday, June 27, 2020, from 10 am to 12 pm in the parking lot of the Vienna Presbyterian Church (124 Park Street, NE, Vienna, VA), and delivery to the VA is scheduled for Tuesday, June 30, 2020, at 10 am.

“Due to the pandemic, many of us unexpectedly found ourselves back in the communities where we had grown up. It became clear that there were urgent needs among Veterans, within our health care system, and among patients in long-term care facilities, and all of us had important social responsibilities to contribute,” said Cadet Suh. “Through our actions and our engagement with our community, we also help address the societal schisms and the racial divide that we are seeing in our country. Working on meaningful activities, on common missions – that is how we bring everyone together. It is an honor to serve the Veterans who have given so much to our nation, together as a unified front.”

                                                                                    # # #

More information about Operation Golden Shield is available at http://www.operationgoldenshield.com.

Share article on social media or email:

Nightingale College Nursing Students Pivot to Online Simulations to Continue their Education Uninterrupted by COVID-19


Nightingale College accelerated its plans to include virtual clinical simulation and at-home skills practice kits as part of their nursing curriculum, helping learners to continue their education without interruption.

In response to the COVID-19 pandemic, Nightingale College accelerated plans to include virtual clinical simulation and at-home skills practice kits as part of their nursing curriculum. This change allowed nursing students to continue their education uninterrupted during the COVID-19 pandemic.

The College recently announced plans to bring nursing education nationwide through its remote Bachelor of Science in Nursing program, allowing students to engage in online learning for the majority of the curriculum time. This program will require students to travel to an on-ground hub, overseen by faculty, once a semester to perform skills pass-offs and experiential learning rotations at healthcare facilities. The College also proudly announced the rapid pivot to online simulations did not require any additional federal funds.

As a result, May 2020 saw the largest starting group of learners across the College’s academic programs, including associate’s and bachelor’s degrees in nursing, as well as RN-to-BSN and master’s in nursing education. Since its inception nearly 10 years ago, Nightingale College has graduated more than 1,000 learners and currently has a student body of more than 1,000 learners in its nursing programs.

“The centerpiece of Nightingale’s mission is to elevate health in the communities we serve by increasing demographic, socioeconomic and geographic access to nursing education,” said Mikhail Shneyder, president and CEO of Nightingale College. “Through technology, nearly anyone, anywhere can enroll into academic programs to start or advance their nursing careers.”

Additionally, Nightingale College announced the availability of two free online courses for health care professionals and consumers, now available here on uCertify. The first course provides information about wellness for the public and covers topics of immediate interest including assessing wellness, nutrition, sleep and exercise, among others, as well as strengthening immune systems and managing COVID-19 infections at home.

The second course, Ventilator Management, provides knowledge to support healthcare professionals who may need deeper background in the management of ventilators, including key topics such as how ventilators function, ventilator operations, scenarios in which ventilators are required, etc. This course features Dr. Robert Arnot’s introduction and highly curated content from the Centers for Disease Control and Kahn Academy.

For more information about Nightingale College and its nursing education programs, click here.

#            #         #

Share article on social media or email: